Medical Microinstruments, a Pisa, Italy-based robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, raised $110M in Series C funding.
The round, which brought the total amount to $200M, was led by Fidelity Management & Research Company.
The company intends to use the funds to support commercialization of the Symani® Surgical System in high-growth markets and continue investment in studies that generate clinical evidence and enable indication expansion.
Led by Mark Toland, CEO, MMI provides robotic technology that opens new opportunities for surgeons to restore quality of life for patients with complex conditions. Its proprietary Symani® Surgical System combines small wristed microinstruments with tremor-reducing and motion-scaling technologies to address microvascular repair, lymphatic repair, and peripheral nerve repair.
The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use.
Commenting on the news, Mark Toland said: “Our Symani Surgical System is uniquely positioned to expand patient access to care by accelerating the number of surgeons able to perform complex, delicate procedures. With the support of our investors, we will continue to advance our technology through a growing body of clinical evidence and expanded hospital partnerships.”
FinSMEs
21/02/2024